Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02251860Completed

Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice

Role: collaborator

NCT02983500Completed

Patient Reported Outcomes Registry in Patient With Cancer Cachexia

Role: collaborator

NCT01457144Phase 2Completed

Study of Mantle Cell Lymphoma Treatment by RiBVD

Role: collaborator

NCT01222546Phase 1Completed

Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors

Role: lead

All 4 trials loaded